About this Type 1 diabetes study
The PROTECT Study is testing how well an investigational medicine, called teplizumab, works in children and adolescents with Type 1 diabetes (T1D). If you or your child are 8–17 years old and have recently been diagnosed with T1D you may be able to take part. Other medical criteria must be met before you can join the study, which will be assessed by the study team.
Treatment with the investigational medicine appears to interfere with the cells (T cells) that destroy the insulin-producing beta cells in the pancreas. By interfering with T cells, individuals with T1D receiving teplizumab may be able to continue making more of their own insulin and reduce the need for insulin injections, have better glucose control and/or fewer complications of T1D, ultimately improving life and outcomes for those with T1D.